Abraham W M, Sabater J R, Szelenyi S, Bähre M
Division of Pulmonary Disease and Critical Care Medicine, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida 33140, USA.
Pulm Pharmacol Ther. 1998;11(4):271-6. doi: 10.1006/pupt.1998.0150.
The purpose of this study was to compare the effectiveness of an eight day treatment with clinically relevant doses of a fixed combination of the beta 2 mimetic reproterol hydrochloride and disodium cromoglycate with each agent given alone against antigen-induced early (EAR) and late airway responses (LAR) as well as post-antigen-induced airway hyperresponsiveness (AHR) in allergic sheep. Animals were treated in a randomized fashion with either the inhaled combination (n = 6), reproterol hydrochloride alone (n = 6), disodium cromoglycate alone (n = 6), or placebo (n = 8). Treatments (two puffs from a metered dose inhaler) were given three times a day for 7 days and once on the 8th day 1 h before airway challenge with Ascaris suum antigen. In the placebo trial, antigen challenge resulted in EAR and LAR as measured by increases in specific lung resistance; these changes were followed 24h later by AHR to inhaled carbachol. With respect to the placebo trial, treatment with reproterol hydrochloride reduced the EAR (P < 0.05) and blocked the LAR (P < 0.05), but had no effect on the post-challenge AHR. Treatment with disodium cromoglycate also reduced the EAR (P < 0.05), blocked the LAR (P < 0.05), and blocked the post-antigen-induced AHR (P < 0.05). Treatment with the fixed combination reduced the EAR (P < 0.05), blocked the LAR (P < 0.05), and blocked the post-antigen-induced AHR (P < 0.05). Comparison of the different agents indicated that the fixed combination gave significantly increased protection against the EAR than either agent alone, gave slightly better (P < 0.05) protection against the late response than cromolyn sodium and gave better protection against post-antigen-induced AHR than reproterol hydrochloride alone. These results suggest that a fixed combination of a beta 2-mimetic and disodium cromoglycate provides some increased protection against antigen-induced airway responses when compared to either agent alone in a controlled laboratory setting.
本研究的目的是比较给予临床相关剂量的β2 拟交感神经药盐酸瑞普特罗和色甘酸二钠的固定组合进行为期八天的治疗,与单独给予每种药物相比,对变应性绵羊抗原诱导的早期(EAR)和晚期气道反应(LAR)以及抗原激发后气道高反应性(AHR)的效果。动物被随机分为吸入组合治疗组(n = 6)、单独使用盐酸瑞普特罗治疗组(n = 6)、单独使用色甘酸二钠治疗组(n = 6)或安慰剂组(n = 8)。治疗(通过定量吸入器喷两下)每天进行三次,共7天,并在第8天用猪蛔虫抗原进行气道激发前1小时给药一次。在安慰剂试验中,抗原激发导致特异性肺阻力增加,从而测得EAR和LAR;24小时后,这些变化继之以对吸入卡巴胆碱的AHR。与安慰剂试验相比,盐酸瑞普特罗治疗可减轻EAR(P < 0.05)并阻断LAR(P < 0.05),但对激发后的AHR无影响。色甘酸二钠治疗也可减轻EAR(P < 0.05)、阻断LAR(P < 0.05)并阻断抗原激发后的AHR(P < 0.05)。固定组合治疗可减轻EAR(P < 0.05)、阻断LAR(P < 0.05)并阻断抗原激发后的AHR(P < 0.05)。不同药物的比较表明,固定组合对EAR的保护作用明显优于单独使用任何一种药物,对晚期反应的保护作用比色甘酸钠略好(P < 0.05),对抗原激发后AHR的保护作用比单独使用盐酸瑞普特罗更好。这些结果表明,在受控实验室环境中,与单独使用任何一种药物相比,β2 拟交感神经药和色甘酸二钠的固定组合对抗原诱导的气道反应提供了一些增强的保护作用。